Literature DB >> 21691879

Is neo-adjuvant chemotherapy a "waiver" of extensive upper abdominal surgery in advanced epithelial ovarian cancer?

Sokbom Kang1, Yoo Heon Jong, Jong Ha Hwang, Myong Cheol Lim, Sang-Soo Seo, Chong-Woo Yoo, Sang-Yoon Park.   

Abstract

BACKGROUND: The goal of this study was to explore the necessity of extensive surgical procedures in patients who received neoadjuvant chemotherapy (NAC).
METHODS: We analyzed the surgical outcomes and frequency of extensive procedures required for maximal cytoreductive surgery after NAC and primary debulking surgery (PDS) in 256 women with advanced epithelial ovarian cancer.
RESULTS: NAC was performed in 116 of 256 women (45.3%). In NAC group, complete cytoreduction rate and optimal cytoreduction rate were 60.3 and 92.2%, respectively. Although the NAC group comprised patients with higher risk of suboptimal cytoreduction, complete cytoreduction rate was similar to that of PDS group (57.9%, P = .69). Moreover, blood loss and surgical complexity significantly reduced in NAC group (P = .011 and .017). Extensive upper abdominal surgery (EUAS) was performed in 70 of 116 patients (60.3%) in the NAC group. The frequency of EUAS was similar between NAC and PDS group (P = .60). Among NAC group, gross upper abdominal metastasis requiring EUAS was found in 51 patients (44%, 95% confidence interval = 35.3-53.1%).
CONCLUSIONS: A significant proportion of patients who received NAC still have gross metastatic tumors requiring EUAS. Gynecologic oncologists should be familiar with EUAS and be ready to perform any required procedures together with multidisciplinary teams, even in the patients who have received NAC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21691879     DOI: 10.1245/s10434-011-1830-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

Review 1.  Role of aggressive surgical cytoreduction in advanced ovarian cancer.

Authors:  Suk Joon Chang; Robert E Bristow; Dennis S Chi; William A Cliby
Journal:  J Gynecol Oncol       Date:  2015-07-17       Impact factor: 4.401

2.  Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer.

Authors:  Myong Cheol Lim; Heong Jong Yoo; Yong Jung Song; Sang Soo Seo; Sokbom Kang; Sun Ho Kim; Chong Woo Yoo; Sang Yoon Park
Journal:  J Gynecol Oncol       Date:  2017-07       Impact factor: 4.401

3.  Microscopic diseases remain in initial disseminated sites after neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and primary peritoneal cancer.

Authors:  Shinichi Tate; Kyoko Nishikimi; Kazuyoshi Kato; Ayumu Matsuoka; Michiyo Kambe; Takako Kiyokawa; Makio Shozu
Journal:  J Gynecol Oncol       Date:  2019-12-09       Impact factor: 4.401

Review 4.  Outcome quality standards in advanced ovarian cancer surgery.

Authors:  Antoni Llueca; Anna Serra; Maria Teresa Climent; Blanca Segarra; Yasmine Maazouzi; Marta Soriano; Javier Escrig
Journal:  World J Surg Oncol       Date:  2020-11-25       Impact factor: 2.754

5.  Aggressive surgery could overcome the extent of initial peritoneal dissemination for advanced ovarian, fallopian tube, and peritoneal carcinoma.

Authors:  Kyoko Nishikimi; Shinichi Tate; Ayumu Matsuoka; Makio Shozu
Journal:  Sci Rep       Date:  2020-12-04       Impact factor: 4.379

6.  Diaphragm hernia after debulking surgery in patients with ovarian cancer.

Authors:  Sarah Ehmann; Emeline M Aviki; Yukio Sonoda; Thomas Boerner; Dib Sassine; David R Jones; Bernard Park; Murray Cohen; Norman G Rosenblum; Dennis S Chi
Journal:  Gynecol Oncol Rep       Date:  2021-03-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.